Effect of Advanced Hybrid Closed Loop System, MiniMed 780G in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study)

Korábbi kezelés

• Illicit drugs abuse.
• Sickle cell disease, haemoglobinopathy, receiving red blood cell transfusion or erythropoietin within 3 months prior to time of enrollment.

Más betegség

• Type 2 diabetes mellitus or MODY diabetes
• Any untreated comorbidities of type 1 diabetes
• Untreated diabetes retinopathy, or other causes that in the investigator's opinion, precludes the individual from participating in the trial.
• Known or suspected allergy to insulin.
• Severe visual or hearing impairment.
• Medically documented allergy to the adhesive of plasters or unable to tolerate tape adhesive around sensor placement.
• Eating disorder including anorexia/bulimia.
• Milk protein allergy.

Laborértékek

• Medication affecting metabolic control or interfering in the interpretation of HbA1c
• Serious skin lesions at areas of the body used for insertion of the glucose sensor.

Egyéb

• Pregnancy
• Regular use of acetaminophen.
• Lack of reliable telephone facility for contact.
• Living alone.
• Alcohol abuse.

• Clinical diagnosis of type 1 diabetes (WHO criteria). Diagnosis of type 1 diabetes is based on international criteria and the investigator's judgment; C peptide level and antibody determinations are not required.
• Age range 7 to 17 years.
• Literate in Greek or English.
• Willing to wear study devices.
• Willing to follow study-specific instructions.
• Total daily insulin dose greater than 8.0 units over 1 week period
• Willing and able (access to internet from home) to download information into the Medtronic CareLink software
• Clinically eligible to start the AHCL system